VivoSeq
Oncology

Refractory Solid Tumor

0

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Refractory Solid Tumor is an early-stage landscape with 0 programs across 3 companies. The most active players are PersonGen BioTherapeutics (Suzhou) Co., Ltd., Bristol-Myers Squibb, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Unknown status5 · 56%
Completed2 · 22%
Not yet recruiting2 · 22%

Clinical Trials

Trial Activity

9 trials

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
Not yet recruiting·BBionoxx Inc.·Phase 1·NCT07190833·27 enrolled
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients
Not yet recruiting·BBionoxx Inc.·Phase 1·NCT07170592·24 enrolled
Phase I (PH I) Mad Refractory Solid Tumor Study
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT00099606·60 enrolled
First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor
Completed·Sanofi logoSanofi·Phase 1·NCT01156870·114 enrolled
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)
Unknown status·RRuijin Hospital·Phase 1·NCT04508686·20 enrolled
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)
Unknown status·RRuijin Hospital·Phase 1·NCT04510818·20 enrolled
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)
Unknown status·RRuijin Hospital·Phase 1·NCT04932187·20 enrolled
CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
Unknown status·PPersonGen BioTherapeutics (Suzhou) Co., Ltd.·Phase 1/2·NCT02839954·10 enrolled
Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
Unknown status·PPersonGen BioTherapeutics (Suzhou) Co., Ltd.·Phase 1/2·NCT02587689·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)